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Background: The impact of KRAS signaling on cancerous inhibitor of protein phosphatase 2A (CIP2A) expression
has not yet been explored. We investigated the impact of KRAS on CIP2A expression in colorectal cancer patients
after colorectal liver metastasectomy.
Methods: We examined CIP2A expression by immunohistochemistry (IHC) and used direct sequencing to identify
the mutational status of KRAS exon 2 (codon 12 and 13). The association between CIP2A expression, KRAS
genotype, clinicopathological parameters and survival were examined by the Kaplan–Meier method and the Cox
proportional hazards model. A combination of immunoblotting and proliferation assays were employed to
elucidate the role of CIP2A in signal transduction pathways in wild-type KRAS Caco-2 cells.
Results: A total of 220 colorectal cancer patients who had undergone colorectal liver metastasectomy were
included in the study. The mutant KRAS genotype was associated with CIP2A overexpression. CIP2A expression was
an independent prognostic marker in patients with wild-type KRAS metastatic colorectal cancer after colorectal liver
metastasectomy (relative risk = 1.873, P = 0.019). Targeted silencing of CIP2A in Caco-2 cells (wild-type KRAS) led to
decreased expression of pERK/ERK and decreased cell proliferation. Overexpression of mutant KRAS G12D in Caco-2 cells
led to an increase in CIP2A expression and cell proliferation. In Caco-2 cells with the KRAS G12D, KRAS overexpression
preserved the regulation effect of CIP2A in KRAS and abrogated the impact of CIP2A regulation on pERK/ERK and cell
proliferation. CIP2A inhibition also increased the efficacy of cetuximab in Caco-2 cells.
Conclusions: CIP2A is an independent prognostic marker in patients with wild-type KRAS metastatic colorectal cancer
after colorectal liver metastasectomy.
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Approximately one-third of patients with colorectal cancer
develop metastatic disease, with metastases commonly oc-
curring in the liver [1,2]. The standard treatment for pa-
tients with colorectal liver metastasis is colorectal liver
metastasectomy [2]; however, the rate of recurrence is* Correspondence: danny_teng@yahoo.com.tw
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patients [3-5]. Thus, the identification of novel oncogenes
or targets as biomarkers for colorectal liver cancer recur-
rence is necessary.
Cancerous inhibitor of protein phosphatase 2A (CIP2A)
is a recently identified oncoprotein that is overexpressed
in several malignancies, including leukemia, breast, gastric,
prostate, lung, ovarian, head and neck carcinoma, and
colorectal cancer [6-21]. CIP2A plays an important role in
cell proliferation, transformation, drug resistance and
maintenance of a malignant cellular phenotype [22].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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factor receptor (EGFR) signaling pathway (Figure 1).
CIP2A expression is positively correlated with EGFR ex-
pression and amplification in serous ovarian cancer [23].
Furthermore, in hepatoma cells, CIP2A expression is also
associated with resistance to the anti-EGFR bio-agent, er-
lotinib (Tarceva), in vitro [24]. It is well documented that
EGFR signaling is the most important pathway in treating
metastatic colorectal cancer [25,26]. Therefore, the inter-
play between EGFR signaling and CIP2A in metastatic
colorectal cancer warrants further investigation.
V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene (KRAS)
is the most important downstream effector in the EGFR
pathway. Approximately 40% of patients with metastatic
colorectal cancer carry KRAS mutations affecting codons
12 and 13 in exon 2 [5]. Indeed, mutation of KRAS is a
predictive marker of cetuximab efficacy in metastatic colo-
rectal cancer patients [26,27]. However, to date, the prog-
nostic value of KRAS mutations in metastatic colorectal
cancer remains inconclusive [5,28-33]. Our previous study
in colorectal cancer cell lines revealed that the KRAS
G12D mutation decreased the impact of CIP2A on down-
stream effectors of the EGFR signaling pathway, when
cells were treated with temsirolimus [34]. To the best of
our knowledge, the interaction between KRAS mutantFigure 1 Model of CIP2A involvement in the EGFR-RAS signaling
pathways. ETS1 mediates CIP2A overexpression in human cancers
with increased EGFR-MEK-ERK pathway activity. A positive feedback
loop of CIP2A and MEK/ERK signaling pathways is shown.status and CIP2A has not been previously explored follow-
ing colorectal liver metastasectomy.
In this study, we therefore investigated the association
of CIP2A expression and KRAS genotype in the context of
colorectal liver metastasectomy. We found that CIP2A
only acts as an independent prognostic marker in patients
with wild-type KRAS metastatic colorectal cancer after
colorectal liver metastasectomy.
Methods
Patients and tissue blocks
A total of 220 patients undergoing colorectal liver metas-
tasectomy at Taipei Veterans General Hospital in Taiwan,
were enrolled in our study between January 2000 and
January 2010. Disease stage was assessed based on the
American Joint Committee on Cancer staging system, 6th
edition. Clinicopathological staging and clinical course
were determined by searching a computer database con-
taining detailed information. The medical residual samples
of patients came from residual sample bank of Taipei
Veterans General Hospital and this study was approved by
the Institutional Review Board of Taipei Veterans General
Hospital (VGHIRB No 2012-03-027BC). Thus, The
VGHIRB waive the requirement of inform consent form.
The decision to perform hepatic resection was made by a
multidisciplinary specialist committee. After hepatic resec-
tion, decisions regarding adjuvant chemotherapy were
made on an individual patient basis at the discretion of
the attending physicians. Patients were followed until the
end of assessment (March 2012) or death, whichever oc-
curred earlier. Patient follow-ups occurred at least every
3 months from the time of hepatic resection for the first
2 years, then every 6 months for the next 5 years, and sub-
sequently annually until the patient’s death. Overall sur-
vival (OS) was defined as the period from liver surgery to
death due to cancer.
Immunohistochemistry (IHC)
CIP2A expression was assessed by IHC using monoclonal
antibodies to CIP2A (NB100-74663, 1:1200; Novus Biologi-
cals, Littleton, CO, USA). IHC staining was performed as
previously described [10]. Negative (no primary antibody)
and positive tissue controls (colon carcinoma) were stained
in parallel with each set of tumor specimens studied.
IHC staining was evaluated by two pathologists who
were unaware of the patients’ clinical information. The
intensity of stained cells was scored as 0, 1, 2 or 3. Per-
centages of stained cells were counted, and a final im-
munohistochemical score (H-score) was calculated by
summing the products of the staining intensities (0–3)
and distributions (0–100%). H-scores ranged from 0–300.
For CIP2A staining, an H-score of ≥ 150 points was de-
fined as strongly positive, whereas an H-score of < 150
points was defined as weakly positive.
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Tumor regions were macrodissected and examined to
confirm that at least 80% of the cells in the tissue were
cancer cells. DNA extraction was performed using a
Nucleon HT DNA extraction kit (Piscataway, NJ, USA),
according to the manufacturer’s instructions. Exon 2 of
KRAS was separately amplified as previously described
[35]. Purified PCR products were sequenced using
the BigDyeR Terminator v3.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA, USA) and ana-
lyzed using a 3730 ABI capillary electrophoresis system
(Applied Biosystems).
Cell culture and transfection
The Caco-2 human colon cancer cell line, harboring
wild-type KRAS (American Type Culture Collection;
ATCC) was maintained in Dulbecco’s Modified Eagle
Medium (Gibco, Grand Island, USA). Cells were main-
tained at 37°C in a humidified atmosphere of air and 5%
CO2. Transfections were performed using Lipofectamine
2000 in accordance with the manufacturer’s protocol
(Invitrogen, Massachusetts, USA). The KRAS wild type
genotype in Caco-2 cells was confirmed by analysis of
KRAS codon 12 and 13 mutations.
Cell viability assay
Caco-2 cells were seeded in 96-well plates (10,000 cells/
well) and after incubation for 12 h, cells were treated
with cetuximab (Merck, Taiwan). Cell viability was then
assessed using the TACS MTT cell proliferation assay kit
(TREVIGEN, Gaithersburg, MD, USA), according to
the manufacturer’s instructions. The dose–response or
time-response curves were analyzed using GraphPad
Software (Institute for Scientific Information, Philadelphia,
PA, USA).
Immunoblot analysis
Immunoblot analysis was performed as previously de-
scribed [10]. The following proteins were evaluated by
immunoblot: CIP2A (1:500; Novus Biologicals, CO,
USA), pERK (1:1000; Cell Signaling Technology, Boston,
MA, USA), ERK (1:5000; Zymed, Grand Island, NY,
USA) and β-actin (1:500; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). β-actin was used as a loading
control. Immunoblot quantification was performed using
Image J software (http://rsb.info.nih.gov/ij/index.html).
Knockdown of CIP2A and KRAS in colon cancer cells
The siRNA construct targeting CIP2A (pLKO.1-shCIP2A,
TRCN0000135532, target sequence: (5′-CCACAGTTTA
AGTGGTGGAAA-3′) and non-targeting siRNA control
(pLKO.1-shLuc) were obtained from the National RNAi
Core Facility, Taiwan (http://rnai.genmed.sinica.edu.tw/index).
Lentivirus production and infection were performed aspreviously described [10]. The KRAS G12D mutant con-
struct (pCMV6-Entry-KRAS G12D, RC400104) and con-
trol vector (pCMV6-AC-GFP, PS100010) were purchased
from Origene (Rockville, Maryland, USA).Statistical and survival analyses
The correlations between clinicopathological variables
and genomic alterations were analyzed by χ2 test or
Fisher’s exact test. Survival was estimated using the
Kaplan–Meier method, and the log-rank test was used
for comparison of survival curves as well as for univari-
ate analysis. The Cox proportional hazards model was
applied for multivariate analyses. Variables with P-
values ≤ 0.010 in the log-rank test were entered in multi-
variate analyses. The t-test was used to compare data
from the proliferation studies. A two-sided P-value of <
0.05 was considered statistically significant. SPSS soft-
ware (version 16.00, SPSS, Chicago, IL, USA) was used
for all statistical analyses.Results
Patient characteristics and association of clinical
parameters with CIP2A expression
A total of 220 patients who had undergone colorectal
liver metastasectomy were enrolled in our study
(Table 1). The median age at diagnosis was 62.0 years
(range: 30–87 years). The median OS after colorectal
liver metastasectomy was 51.0 months, and the 5-year
survival rate was 52.7%. To investigate the association
between CIP2A expression and patient clinical parame-
ters, CIP2A expression was examined in colorectal liver
metastases sections by IHC staining (representative im-
ages are shown in Figure 2a and b). Ninety-one patients
(41.4%) exhibited strong CIP2A expression. CIP2A ex-
pression was not significantly correlated with sex, age,
initial stage at diagnosis, location of primary tumor,
pathology, grade, margin, distribution of liver metastasis,
number of liver metastases, size of liver metastasis or ex-
trahepatic metastasis. However, CIP2A overexpression
was associated with KRAS mutation status (P < 0.001).
Among patients with KRAS codon 12 mutations, 57.6%
exhibited strong CIP2A expression. Among patients with
KRAS codon 13 mutations, 54.5% exhibited strong CIP2A
expression. Only 30.5% of patients with the wild-type
KRAS genotype exhibited strong CIP2A expression.
The intensity of CIP2A staining in paired colon cancer
and colorectal liver metastasis samples was also com-
pared in 24 patients (representative images are shown in
Figure 2c and d). CIP2A expression was similar between
paired colon cancer and colorectal liver metastasis sam-
ples, with no significant difference in H-score between
primary and metastatic tumors (Figure 2e).
Table 1 Association between clinicopathological
parameters and CIP2A expression in patients after
colorectal liver metastasectomy





n (%) n (%) P-value
Sex Female 44 (53.7) 38 (46.3) 0.248
Male 85 (61.6) 53 (38.4)
Age (y/o) ≤65 80 (63.5) 46 (36.5) 0.090
>65 49 (52.1) 45 (47.9)
Initial stage
at diagnosis
I-III 57 (44.2) 30 (33.0) 0.094
IV 72 (55.8) 61 (67.0)
Location Colon 88 (57.5) 65 (42.5) 0.610
Rectum 41 (61.2) 26 (38.8)
Pathology Adenocarcinoma 127 (59.6) 86 (40.4) 0.101
Mucinous
adenocarcinoma
2 (28.6) 5 (71.4)
Grade Low 121 (93.8) 90 (98.9) 0.060
High 8 (6.2) 1 (1.1)
Margin R0-1 125 (96.9) 88 (96.7) 0.935
R2 4 (3.1) 3 (3.3)
Distribution Unilateral 113 (59.8) 76 (40.2) 0.392
Bilateral 16 (51.6) 15 (48.4)
Number ≤3 101 (60.1) 67 (39.9) 0.422
>3 28 (53.8) 24 (46.2)
Size (cm) ≤5 107 (59.8) 72 (40.2) 0.473
>5 22 (53.7) 19 (46.3)
Extrahepatic
metastasis
No 107 (82.9) 74 (81.3) 0.756
Yes 22 (17.1) 17 (18.7)
KRAS Wild-type 91 (69.5) 40 (30.5) <0.001
Codon 12 mutation 28 (42.4) 38 (57.6)
G12D 13 (40.6) 19 (59.4)
G21V 7 (41.2) 10 (58.8)
G12C 5 (41.7) 7 (58.3)
G12R 1 (100.0) 0 (0.0)
G12S 2 (50.0) 2 (50.0)
Codon 13 mutation 10 (45.5) 12 (54.5)
G13D 9 (45.0) 11 (55.0)
G13C 0 (0.0) 1 (100.0)
G13V 1 (100.0) 0 (0.0)
Codon 14 mutation 0 (0.0) 1 (100.0)
V14I 0 (0.0) 1 (100.0)
Abbreviations: CIP2A Cancerous inhibitor of protein phosphatase 2A, KRAS v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog.
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multivariate analyses in patients after colorectal
liver metastasectomy
To clarify the role of CIP2A in patients following colo-
rectal liver metastasectomy, the Cox proportional haz-
ards model was applied (Table 2). In the univariate
model, initial stage at diagnosis, number of colorectal
liver metastases, margin and CIP2A expression (hazard
ratio [HR] = 1.447, P = 0.049) were prognostic factors.
However, in the multivariate model, CIP2A expression
was not an independent prognostic factor after con-
trolling for other risk factors (HR = 1.373, P = 0.096).
Impact of CIP2A levels on OS in patients after colorectal
liver metastasectomy according to KRAS genotype
OS after colorectal liver metastasectomy was signifi-
cantly worse in patients with strong CIP2A expression
compared with those with weak CIP2A expression, in
patients with wild-type KRAS (Figure 3a, P = 0.035). In
contrast, we observed no difference in OS between
strong and weak CIP2A expression in patients with mu-
tant KRAS (Figure 3b, P = 0.759).
Prognostic factors for OS according to univariate and
multivariate analyses in patients with wild-type KRAS
after colorectal liver metastasectomy
To clarify the role of CIP2A in patients exhibiting the
wild-type KRAS genotype, the Cox proportional haz-
ards model was applied (Table 3). In the univariate
model, the number of colorectal liver metastases,
grade, margin and CIP2A expression were prognostic
factors, whereas age, initial stage at diagnosis, distribu-
tion, size of colorectal metastases and extrahepatic me-
tastasis were not. Significant factors in the univariate
model were subsequently used in the multivariate
model. After controlling for other risk factors, CIP2A
expression was still an independent prognostic factor
in patients with wild-type KRAS genotype (HR = 2.109,
P = 0.006).
Association of CIP2A expression, KRAS genotype,
cetuximab and proliferation in wild-type KRAS Caco-2
colon cancer cells
To explain our clinical findings, we conducted add-
itional studies in Caco-2 colon cancer cells, which ex-
press wild-type KRAS. Targeted silencing of CIP2A
using shCIP2A led to decreased expression of CIP2A,
KRAS, and pERK (Figure 4a), and a concomitant de-
crease in cell proliferation (Figure 4b, P = 0.013). Over-
expression of mutant KRAS (pCMV6-KRAS G12D,
Figure 4a) led to increased expression of KRAS,
CIP2A, and pERK, and increased cell proliferation
(Figure 4b, P = 0.043). While targeted silencing of
CIP2A also led to decreased CIP2A expression in cells
Figure 2 Immunohistochemical (IHC analysis of CIP2A expression in patients with colorectal cancer. Representative examples of CIP2A expression:
(a) strong expression in colorectal liver metastasis, (b) weak expression in colorectal liver metastasis, (c) staining in paired colon cancer, (d) colorectal
metastasis tissues, and (e) H-score in paired colon cancer and liver metastasis samples. CIP2A was not consistently overexpressed in colon cancer
compared with colorectal liver metastasis in paired tissue specimens.
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did not observe a decrease in the expression of pERK/
ERK or a significant decrease in proliferation. Last, the
efficacy of cetuximab in Caco-2 cells increased after
CIP2A knockdown compared with control (Figure 5).Table 2 Prognostic factors for overall survival according to un
wild-type and mutant KRAS metastatic colorectal cancer after
n = 220 Univariate
Variable Hazard ratios (95% CI)
Age > 65 (y/o) 1.055 (0.729–1.526)
Initial stage IV at diagnosis 1.668 (1.129–2.462)
Bilobar liver metastases 1.494 (0.902–2.475)
Size > 5 cm 1.268 (0.803–2.002)
Number > 3 1.932 (1.287–2.903)
High grade 1.385 (0.915–2.096)
Margin R2 3.112 (1.350–7.172)
Extrahepatic metastasis 1.462 (0.937–2.282)
CIP2A overexpression 1.447 (1.001–2.092)
Abbreviations: CIP2A Cancerous inhibitor of protein phosphatase 2A, KRAS v-Ki-ras2Discussion
To the best of our knowledge, this is the first study to re-
port an association between CIP2A expression and KRAS
genotype in patients with metastatic colorectal cancer
after colorectal liver metastasectomy. After adjusting forivariate and multivariate analyses in patients with both
colorectal liver metastasectomy
Multivariate
P-value Hazard ratios (95% CI) P-value
0.778 — —
0.010 1.336 (0.885–2.016) 0.168
0.119 — —
0.309 — —
0.002 1.753 (1.151–2.670) 0.009
0.123 — —
0.008 2.087 (1.200–6.567) 0.017
0.094 1.255 (0.798–1.973) 0.326
0.049 1.373 (0.946–1.992) 0.096
Kirsten rat sarcoma viral oncogene homolog.
Figure 3 Kaplan–Meier survival plot of overall survival (OS) by KRAS genotype. (a) OS was significantly worse in patients with wild type KRAS and
strong CIP2A expression, compared with patients with wild type KRAS and weak CIP2A expression (P = 0.035). (b) No difference in OS associated
with CIP2A expression was observed in mutant KRAS patients (P = 0.759).
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an independent prognostic marker in patients with wild-
type KRAS metastatic colorectal cancer after colorectal
liver metastasectomy.
Overexpression of CIP2A is associated with tumor ag-
gressiveness, lymph node and lymphovascular involve-
ment, and advanced stage colon cancer, which may
partially explain why CIP2A functions as a prognostic
marker in patients with wild-type KRAS metastatic colo-
rectal cancer after colorectal liver metastasectomy [10,36].
CIP2A overexpression is also associated with colon cancer
cell proliferation, tumorigenesis in vitro, and resistance to
cetuximab, 5-fluorouracil, oxaliplatin and SN38 (an active
metabolite of irinotecan) [10,34]. Cetuximab, 5-fluorouracil,
oxaliplatin and irinotecan are commonly used for post-
operative chemotherapy after colorectal liver metastasect-
omy or for salvage chemotherapy in the treatment of
metastatic colorectal cancer [3].
In our analysis, the value of CIP2A as a prognostic
marker was limited to patients with wild-type KRAS
metastatic colorectal cancer after colorectal liverTable 3 Prognostic factors for overall survival according to un
wild-type KRAS metastatic colorectal cancer after colorectal l
n = 131 Univariate
Variable Hazard ratios (95% CI)
Age > 65 (y/o) 1.045 (0.627–1.742)
Initial stage IV at diagnosis 1.660 (0.999–2.757)
Bilobar liver metastases 1.049 (0.477–2.308)
Size > 5 cm 0.865 (0.411–1.820)
Number > 3 2.045 (1.167–3.586)
High grade 1.863 (1.032–3.362)
Margin R2 3.559 (1.092–11.600)
Extrahepatic metastasis 1.472 (0.782–2.771)
CIP2A over-expression 1.751 (1.041–2.946)
Abbreviations: CIP2A Cancerous inhibitor of protein phosphatase 2A, KRAS v-Ki-ras2metastasectomy. This observation may be explained by
multiple previous reports. First, Zhao et al. investigated
Helicobacter pylori infection-induced CIP2A expres-
sion, and determined that it was dependent on RAS/
mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK) pathways, indicating that
EGFR pathway activation increased CIP2A expression
[37]. Khanna et al. [38] further concluded that CIP2A
overexpression was dependent on the EGFR-ERK-ETS1
signaling pathway. Both studies illustrate that the EGFR
pathway interacts with CIP2A in vitro and that the
interaction is bi-directional. Furthermore, studies by
Bockelman et al. demonstrated that EGFR protein ex-
pression and amplification were associated with CIP2A
overexpression in vivo [23]. Similarly, we observed that
a mutant KRAS genotype was associated with CIP2A
overexpression. Finally, in colorectal cancer, the EGFR/
RAS pathway is an important signaling pathway. KRAS
is well established as an important downstream effector
of the EGFR signaling pathway, and mutational activa-
tion of KRAS by further active downstream effectorsivariate and multivariate analyses in patients with
iver metastasectomy
Multivariate
P-value Hazard ratios (95% CI) P-value
0.865 — —
0.050 1.445 (0.856–2.439) 0.168
0.905 — —
0.703 — —
0.013 2.084 (1.200–3.621) 0.009
0.039 2.031 (1.101–3.744) 0.023
0.035 3.701 (1.111–12.330) 0.033
0.231 — —
0.035 2.109 (1.236–3.600) 0.006
Kirsten rat sarcoma viral oncogene homolog.
Figure 4 Interaction between CIP2A, KRAS genotype and proliferation in the Caco-2 KRAS wild-type cell line. The result of immunoblot and proliferation
assay is shown in (a) and (b), respectively. Column 1 vs. 2: CIP2A knockdown by shCIP2A resulted in decreased CIP2A, KRAS, and pERK expression as well
as decreased proliferation; Column 1 vs. 3: KRAS overexpression by pCMV6-KRAS G12D resulted in increased KRAS, CIP2A, and pERK expression, as well as
increased proliferation; Column 3 vs. 4: in Caco-2 cells with KRAS overexpression by pCMV6-KRAS G12D, knockdown of CIP2A by shCIP2A resulted in
decreased CIP2A and KRAS expression. However, it did not cause significantly decreased pERK expression or decreased proliferation (*P < 0.05).
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(for example, cetuximab) [39]. The results of our cellu-
lar experiments support this finding. Indeed, we ob-
served that targeted silencing of CIP2A in Caco-2 cells
expressing mutant KRAS G12D led to decreased expres-
sion of CIP2A expression but not pERK/ERK. Overexpres-
sion of mutant KRAS G12D impaired the suppression of
pERK/ERK and effects on cell proliferation mediated byFigure 5 Silencing of CIP2A in Caco-2 cells leads to decreased resistance t
(shLuc) and CIP2A knockdown (shCIP2A) cells.CIP2A silencing. Based on the above results, CIP2A acts
as a prognostic marker in patients with wild-type KRAS
metastatic colorectal cancer following colorectal liver
metastasectomy, because the mutational activation of
KRAS weakens CIP2A regulation on cell survival.
One constraint of our study is that a limited number
of patients received cetuximab (EGFR antagonist) as a
bio-chemotherapy throughout the entire course ofo cetuximab. Immunoblot analysis of CIP2A expression in control
Chen et al. BMC Cancer  (2015) 15:301 Page 8 of 9treatment. Thus, we could not demonstrate that CIP2A
expression is a predictive marker of response to cetuxi-
mab in metastatic colorectal cancer patients with wild-
type KRAS. Further studies are therefore required to
investigate this relationship.
Conclusions
Mutant KRAS is associated with CIP2A overexpression.
CIP2A is an independent prognostic marker in patients
with metastatic colorectal cancer exhibiting wild-type
KRAS after colorectal liver metastasectomy.
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